Metraipolis › archive › dc_6c5a997b032d
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive… — Europe PMC PMID:41570392
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41570392
- DOI
- 10.1016/j.tjpad.2026.100480
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T15:13:17.374Z
- SHA-256 of the archived text
9b0ae5c5e5b730b28ab49093a346847292d505fa2591bbe2fe018987f9f6a58f- Stable URL of this page
https://metraipolis.com/documento/dc_6c5a997b032d
How to cite
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive… — Europe PMC PMID:41570392 — Europe PMC (en), https://europepmc.org/article/MED/41570392 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6c5a997b032d (Metraipolis archive dc_6c5a997b032d, sha256 9b0ae5c5e5b730b28ab49093a346847292d505fa2591bbe2fe018987f9f6a58f)
BibTeX
@misc{dc6c5a997b032d,
title = {Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive… — Europe PMC PMID:41570392},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41570392},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6c5a997b032d; sha256 9b0ae5c5e5b730b28ab49093a346847292d505fa2591bbe2fe018987f9f6a58f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41570392. Agents can read the archived copy with the MCP tool read_document.